In Focus this month:
- Study Identifies Drug Regimen for Preventing Vertical Transmission (NIH)
The ongoing PROMISE (Promoting Maternal-Infant Survival Everywhere) trial compared the safety and effectiveness of three drug regimens for preventing vertical transmission of HIV. The National Institutes of Health reported findings supporting the provision of a lamivudine-based triple drug regimen to all HIV-positive pregnant women.
- New Technologies Enhance HIV Response (PLOS ONE)
The authors modeled the impact of adding new prevention technologies (test and treat, pre-exposure prophylaxis, and HIV vaccination) to HIV treatment in 24 countries. The model showed that while implementation of the 2013 World Health Organization treatment guidelines showed the greatest potential impact, the addition of new prevention technologies could reduce new infections to as low as 80,000 per year by 2050.
- Prevention Package for Men Who Have Sex with Men in South Africa (PLOS ONE)
Modeling revealed that a combination package consisting of 50 percent antiretroviral therapy coverage for eligible persons, 50 percent pre-exposure prophylaxis for high-risk persons, a 15 percent reduction in unprotected anal intercourse, and a 50 percent increase in HIV testing among men who have sex with men could prevent 34 percent of HIV infections over a five-year period.